A New Weapon Against Chronic Migraine
Chronic migraine sufferers may soon have a powerful new treatment option. Results from the Phase 3 LIBERTY-CM trial, published in The Lancet Neurology, show that the oral medication atogepant extended-release (brand name Qulivaro) reduced monthly migraine days by an average of 75% in patients with chronic migraine — a result that neurologists are calling exceptional for a preventive therapy.
Trial Design and Results
The double-blind, placebo-controlled trial enrolled 1,420 adults with chronic migraine, defined as 15 or more headache days per month with at least eight meeting migraine criteria. Participants were randomized to receive either Qulivaro 120mg once daily or placebo for 24 weeks.
The results surpassed expectations:
- Qulivaro group experienced a reduction from an average of 18.2 to 4.6 monthly migraine days
- 62% of patients achieved a 75% or greater reduction in monthly migraine days
- 31% achieved complete freedom from migraine during the final month of the trial
- Improvement began within the first week and continued to increase throughout the study period
- Placebo group saw a reduction from 18.0 to 13.4 monthly migraine days
How Qulivaro Works
Qulivaro belongs to the gepant class of medications, which block calcitonin gene-related peptide (CGRP) receptors. CGRP is a neuropeptide that plays a central role in migraine pathophysiology, contributing to pain signaling, blood vessel dilation, and neurogenic inflammation. The extended-release formulation maintains consistent receptor blockade throughout the day, which researchers believe accounts for its superior efficacy compared to earlier gepants.
The magnitude of the response we saw in this trial is genuinely unprecedented for a preventive migraine therapy. To have more than 60% of chronic migraine patients achieve a 75% reduction in attacks with an oral medication is remarkable. — Dr. Peter Goadsby, Professor of Neurology, King's College London
Advantages Over Existing Treatments
Current preventive migraine treatments include older medications repurposed from other conditions, such as beta-blockers, antidepressants, and anti-seizure drugs, as well as newer CGRP monoclonal antibody injections. Each has significant limitations. The older drugs carry substantial side effect burdens including weight gain, cognitive impairment, and fatigue. The injectable CGRP antibodies, while effective, require monthly or quarterly injections and can be difficult to access due to insurance restrictions.
Qulivaro offers several potential advantages: it is taken orally once daily, demonstrated a favorable side effect profile in trials, and showed rapid onset of action. The most common adverse events were constipation (8%), nausea (5%), and fatigue (4%), all of which were generally mild and transient.
The Road to Approval
AbbVie, which developed the medication, has submitted a New Drug Application to the FDA with a priority review designation. If approved on the expected timeline, Qulivaro could be available by prescription in Q4 2026. The company has indicated pricing will be competitive with existing CGRP-targeting therapies, though specific figures have not been announced.
What This Means for Migraine Patients
For the approximately 4 million Americans living with chronic migraine, the prospect of a highly effective oral preventive represents a significant advance. Many patients have cycled through multiple preventive medications with limited success, and the high response rate observed in the trial suggests Qulivaro may help patients who have not responded adequately to other treatments.
Neurologists caution that individual results will vary and that no single medication works for everyone. However, the expanding toolkit of migraine-specific treatments represents a dramatic improvement from just a decade ago, when options were far more limited and less targeted. Patients interested in Qulivaro should discuss it with their neurologist as more information becomes available about potential access and eligibility.
